{"filings":[{"id":91698,"accession_number":"0001628280-26-028601","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q1 net product revs $1.04B (+121%); GAAP EPS $1.51 vs -$0.14; reaffirms FY26 guidance","event_type":"earnings","confidence":"high","bullets":["Global net product revenues $1,036M, up 121% YoY; total TTR revenues $910M (+153%).","GAAP net income $206M vs loss $18M; GAAP diluted EPS $1.51; non-GAAP EPS $1.99.","Reiterates FY26 combined net product revenue guidance of $4.9B-$5.3B.","AMVUTTRA (vutrisiran) net product revenues $890M; TRITON-CM expanded to ~1,750 patients.","Initiated Phase 1 obesity trial (ALN-2232) and new collaborations with Viz.ai, AHA, Tenaya, Helix."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101952,"accession_number":"0001628280-26-014728","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alnylam grants CEO Greenstreet performance-based PSUs tied to $500-$800 stock price by 2029","event_type":"leadership","confidence":"high","bullets":["Target of 55,373 PSUs ($18.0M face value at $325.07 close on grant date).","Vesting requires 30-day avg stock price of $500 (50% vest) to $800 (200% vest) by Dec 31, 2029.","Baseline threshold of $500 exceeds all-time high; award forfeited if price below $500.","Special award granted alongside annual equity, designed with independent compensation consultant.","Under Greenstreet, Alnylam achieved ~100% stockholder return, AMVUTTRA approval, and 2025 profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101951,"accession_number":"0001628280-26-007491","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam posts Q4 net product rev $995M (+121%); achieves full-year GAAP profitability","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net product revenue $995M (+121% YoY); full-year $2,987M (+81%); total revenue Q4 $1.1B.","GAAP net income $111.5M ($0.82 diluted EPS) vs. loss a year ago; full-year GAAP net income $313.7M.","Non-GAAP operating income $849.8M for FY2025; company expects sustainable operating income growth.","AMVUTTRA (ATTR-CM) drove TTR franchise: Q4 $827M, full year $2,314M (+103% YoY).","Launches 'Alnylam 2030' strategy; plans $250M manufacturing expansion; board appoints Stuart Arbuckle."],"consensus_eps_estimate":null,"consensus_eps_actual":2.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":3713937000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101950,"accession_number":"0001628280-26-001755","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam reports preliminary 2025 net product revs $2,987M (+81% YoY); guides 2026 revs $4.9B-$5.3B","event_type":"earnings","confidence":"high","bullets":["Preliminary 2025 net product revenue $2,987M (81% growth vs 2024); TTR franchise $2,487M (103% growth).","2026 combined net product revenue guidance $4.9B–$5.3B (71% growth at midpoint); TTR guidance $4.4B–$4.7B.","New 'Alnylam 2030' strategy targets 25%+ total revenue CAGR and ~30% non-GAAP operating margin by 2030.","Pipeline goals: nucresiran Phase 3 in ATTR-CM/polyneuropathy; mivelsiran Phase 2 enrollment in H1 2026.","Preliminary Q4 2025: total TTR revs ~$859M (AMVUTTRA $827M, ONPATTRO $32M); total rare revs ~$137M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":3713937000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118284,"accession_number":"0001193125-25-315047","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alnylam repurchases $34.4M of 1.00% convertible notes due 2027 for ~$51.9M","event_type":"debt","confidence":"high","bullets":["Repurchased $34.4M aggregate principal of 1.00% convertible senior notes due 2027 for total cash cost of approximately $51.9M, including accrued interest.","Remaining outstanding principal after repurchases is $362.8M.","Repurchase price is subject to adjustment based on daily VWAP over a measurement period starting December 11, 2025.","Existing capped call transactions entered upon note issuance remain in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118283,"accession_number":"0001628280-25-055084","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alnylam board changes: Bonney and Bertozzi resign; Arbuckle appointed director","event_type":"leadership","confidence":"high","bullets":["Mike Bonney and Carolyn Bertozzi resigned from Alnylam board effective Dec 2, 2025; no disagreement with company.","Bertozzi resigned due to election to Eli Lilly board (eff. Dec 8, 2025); will continue as scientific advisor.","Stuart Arbuckle (ex-Vertex COO) elected to board, effective Jan 5, 2026; receives $75K annual cash retainer plus stock.","Board size reduced from 11 to 10 following resignations; Arbuckle serves as Class I director until 2026 annual meeting.","Arbuckle brings commercial and leadership experience from GSK, Amgen, and Vertex; also serves on Rhythm Pharma board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118282,"accession_number":"0001628280-25-047342","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q3 net product rev $851M (+103% YoY); raises 2025 guidance 10% to $2.95-3.05B","event_type":"earnings","confidence":"high","bullets":["Total net product revenues $851M (+103% YoY); TTR franchise $724M (+135% YoY) led by AMVUTTRA ATTR-CM launch.","GAAP net income $251M ($1.84 diluted EPS) vs loss of $111.6M; non-GAAP net income $396M ($2.90 EPS).","2025 guidance raised: total net product revs $2.95B-$3.05B (10% midpoint increase); TTR rev guidance $2.475B-$2.525B.","Initiated ZENITH Phase 3 for zilebesiran in hypertension and TRITON-PN Phase 3 for nucresiran in hATTR-PN.","Appointed Bryan Supran EVP & Chief Legal Officer; issued $661M convertible notes; received subpoena on government price reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":2616904000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118281,"accession_number":"0001193125-25-230201","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Alnylam enters $500M revolving credit facility maturing 2030","event_type":"debt","confidence":"high","bullets":["New $500M Revolving Credit Facility includes $150M letter of credit sublimit; available for working capital and general corporate purposes.","Interest rates: Term SOFR plus 1.50%–2.50% (based on Total Leverage Ratio); commitment fee 0.20%–0.35% on unused commitments.","Financial covenants: Total Net Leverage Ratio ≤ 3.75:1.00 and Consolidated Interest Coverage Ratio ≥ 3.00:1.00, tested quarterly.","Maturity September 30, 2030; springing maturity if outstanding Springing Maturity Debt exceeds $630M or 100% of EBITDA.","Guaranteed by material domestic subsidiaries and secured by substantially all assets, subject to customary exceptions and release conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134733,"accession_number":"0001193125-25-202366","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Alnylam issues $661.25M zero-coupon convertible notes due 2028; repurchases $637.8M of existing notes","event_type":"debt","confidence":"high","bullets":["Issued $661.25M aggregate principal of 0.00% Convertible Senior Notes due 2028; initial conversion price $670.11/share (~40% premium).","Capped call transactions entered to offset dilution; cost $35.3M, cap price $837.61/share (~75% premium).","Repurchased $637.8M of existing 1.00% convertible notes due 2027 for ~$1,105.8M total (including accrued interest).","Notes mature Sept 15, 2028, no regular interest; settlement in cash, shares, or combination at Alnylam's election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134732,"accession_number":"0001193125-25-199686","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alnylam prices $575M zero-coupon convertible notes due 2028; repurchases $637.8M of 2027 notes","event_type":"debt","confidence":"high","bullets":["$575M principal of 0.00% convertible senior notes due 2028 priced; initial conversion price ~$670.11/share, 40% premium to VWAP.","Net proceeds ~$561.6M; ~$30.7M used for capped call transactions with cap price ~$837.61/share (75% premium).","Concurrently repurchased ~$637.8M of existing 1.00% convertible notes due 2027 for ~$1,105.8M including accrued interest.","Offering upsized from earlier $500M announcement; initial purchasers have option for additional $86.25M.","Closing expected Sept 12, 2025; notes mature Sept 15, 2028; redeemable after Sept 20, 2027 if stock >130% conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134731,"accession_number":"0001178670-25-000089","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q2 net product rev $672M (+64% YoY); TTR franchise $544M (+77%); raises FY guidance","event_type":"earnings","confidence":"high","bullets":["Q2 net product revenues $672M, +64% YoY; TTR franchise $544M (+77%) driven by AMVUTTRA sales of $492M.","GAAP loss from operations $16M vs income $49M in Q2 2024; non-GAAP income from operations $95M.","Raised FY2025 guidance: TTR revenue to $2.175-2.275B; total net product revenue to $2.65-2.8B (+27% at midpoint).","~1,400 ATTR-CM patients on AMVUTTRA as of June 30; approvals secured in EU, UK, Brazil, and Japan.","Initiated TRITON-CM Phase 3 trial for nucresiran in ATTR-CM; received FDA Fast Track designation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":1367878000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151638,"accession_number":"0001178670-25-000076","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alnylam promotes Pushkal Garg to Chief R&D Officer; merges R&D functions","event_type":"leadership","confidence":"high","bullets":["Pushkal Garg appointed EVP, Chief Research and Development Officer to lead integrated R&D organization.","Kevin Fitzgerald's role expanded to include external innovation; receives one-time RSU grant of $2.5M.","Garg's base salary set at $825,000 with STI target of 65% of base; LTI target to be determined.","Fitzgerald's STI target increased to 60% of base salary.","Alnylam targets delivering RNAi therapeutics to all major tissues by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}